26 related articles for article (PubMed ID: 8289494)
1. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer.
Wang Y; Ronckers CM; van Leeuwen FE; Moskowitz CS; Leisenring W; Armstrong GT; de Vathaire F; Hudson MM; Kuehni CE; Arnold MA; Demoor-Goldschmidt C; Green DM; Henderson TO; Howell RM; Ehrhardt MJ; Neglia JP; Oeffinger KC; van der Pal HJH; Robison LL; Schaapveld M; Turcotte LM; Waespe N; Kremer LCM; Teepen JC;
Nat Med; 2023 Sep; 29(9):2268-2277. PubMed ID: 37696934
[TBL] [Abstract][Full Text] [Related]
2. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
Nickel RS; Keller F; Bergsagel J; Cooper T; Daves M; Sabnis H; Lew G
Pediatr Blood Cancer; 2014 May; 61(5):810-4. PubMed ID: 24357218
[TBL] [Abstract][Full Text] [Related]
4. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G; Tröger A; Göbel U; Graubner U; Pekrun A; Jorch N; Kaspers G; Zimmermann M; zur Stadt U; Kazemier K; Pieters R; Den Boer ML; Horstmann M; Janka GE;
Haematologica; 2011 Jun; 96(6):854-62. PubMed ID: 21330320
[TBL] [Abstract][Full Text] [Related]
5. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
Klumper E; Pieters R; den Boer ML; Huismans DR; Loonen AH; Veerman AJ
Br J Cancer; 1995 Jun; 71(6):1188-93. PubMed ID: 7779709
[TBL] [Abstract][Full Text] [Related]
6. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
Kaspers GJ; Kardos G; Pieters R; Van Zantwijk CH; Klumper E; Hählen K; de Waal FC; van Wering ER; Veerman AJ
Leukemia; 1994 Jul; 8(7):1224-9. PubMed ID: 8035616
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Escherich G; Zimmermann M; Janka-Schaub G;
Pediatr Blood Cancer; 2013 Feb; 60(2):254-7. PubMed ID: 22948968
[TBL] [Abstract][Full Text] [Related]
8. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
[TBL] [Abstract][Full Text] [Related]
9. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.
Klumper E; Pieters R; Kaspers GJ; Huismans DR; Loonen AH; Rottier MM; van Wering ER; van der Does-van den Berg A; Hählen K; Creutzig U
Leukemia; 1995 Nov; 9(11):1864-9. PubMed ID: 7475276
[TBL] [Abstract][Full Text] [Related]
10. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.
Dunn CJ; Goa KL
Drugs Aging; 1996 Aug; 9(2):122-47. PubMed ID: 8820798
[TBL] [Abstract][Full Text] [Related]
12. Cellular drug resistance in childhood leukemia.
Veerman AJ; Kaspers GJ; Pieters R
Ann Hematol; 1994; 69 Suppl 1():S31-4. PubMed ID: 8061109
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
